PAVmed (NASDAQ:PAVM) PT Lowered to $21.00

PAVmed (NASDAQ:PAVM) had its price target lowered by equities research analysts at Ascendiant Capital Markets from $22.00 to $21.00 in a report issued on Tuesday, Benzinga reports. The firm presently has a “buy” rating on the stock.

Separately, Lake Street Capital upgraded shares of PAVmed to a “strong-buy” rating in a report on Wednesday, May 15th.

PAVmed Stock Up 9.2 %

PAVM stock opened at $1.19 on Tuesday. The firm has a market cap of $12.39 million, a PE ratio of -0.13 and a beta of 0.66. The business has a 50 day moving average of $0.88 and a 200-day moving average of $1.50. PAVmed has a 12-month low of $0.60 and a 12-month high of $9.00.

PAVmed (NASDAQ:PAVM) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.84) earnings per share (EPS) for the quarter. The business had revenue of $0.98 million during the quarter. On average, research analysts expect that PAVmed will post -5.88 earnings per share for the current year.

PAVmed Company Profile

PAVmed Inc focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck.